Table 3. Contingency tables regarding the answers to questions Q1 and Q2 (World Health Organization Quality of Life Brief Version {WHOQOL-BREF} questionnaire).

Group HF-S/V, patients undergoing treatment with sacubitril/valsartan; Group HF-CT, patients receiving conventional therapy

Answer	Group HF-CT	Group HF-S/V	P-value	Group HF-CT	Group HF-S/V	P-value
	Q1	Q1		Q2	Q2
Very poor, N (%)	-	-	-	-	1 (1.81)	-
Poor, N (%)	44 (22.34)	19 (34.54)	0.0016	39 (19.80)	17 (30.90)	0.003
Neither poor nor good, N (%)	63 (31.98)	21 (38.18)	<0.0001	66 (33.50)	20 (36.36)	<0.0001
Good, N (%)	87 (44.16)	14 (25.45)	<0.0001	89 (45.18)	16 (29.09)	<0.0001
Very good, N (%)	3 (1.52)	1 (1.81)	0.31	3 (1.52)	1 (1.81)	0.31